Akebia Therapeutics, Inc. (AKBA) SEC filings

AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30

$0.47−0.02 (-4.78%)

Close on Nov 13, 2026Market cap $131.40MP/E –Yield –

SEC filings

40 of Akebia Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Oct 21, 2026	Oct 23, 2026	SEC EDGAR
Current report	8-K	Oct 7, 2026	Oct 14, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Aug 5, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Jun 30, 2026	Jun 30, 2026	SEC EDGAR
Current report	8-K	Jun 17, 2026	Jun 22, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 28, 2026	Apr 28, 2026	SEC EDGAR
Current report	8-K	Mar 27, 2026	Apr 1, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 26, 2026	SEC EDGAR
Current report	8-K	Feb 26, 2026	Feb 26, 2026	SEC EDGAR
Current report	8-K	Jan 27, 2026	Jan 30, 2026	SEC EDGAR
Current report	8-K	Jan 12, 2026	Jan 12, 2026	SEC EDGAR
Current report	8-K	Nov 28, 2025	Dec 1, 2025	SEC EDGAR
Current report	8-K	Nov 12, 2025	Nov 17, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 10, 2025	SEC EDGAR
Current report	8-K	Nov 10, 2025	Nov 10, 2025	SEC EDGAR
Current report	8-K	Oct 28, 2025	Oct 28, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Jun 10, 2025	Jun 13, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 8, 2025	SEC EDGAR
Current report	8-K	May 8, 2025	May 8, 2025	SEC EDGAR
Proxy statement	DEF 14A	Apr 29, 2025	Apr 29, 2025	SEC EDGAR
Current report	8-K	Mar 19, 2025	Mar 20, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 13, 2025	SEC EDGAR
Current report	8-K	Mar 13, 2025	Mar 13, 2025	SEC EDGAR
Current report	8-K	Feb 3, 2025	Feb 7, 2025	SEC EDGAR
Current report	8-K	Jan 13, 2025	Jan 13, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 7, 2024	SEC EDGAR
Current report	8-K	Nov 7, 2024	Nov 7, 2024	SEC EDGAR
Current report	8-K	Oct 22, 2024	Oct 22, 2024	SEC EDGAR
Current report	8-K	Oct 15, 2024	Oct 16, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Aug 8, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Jul 10, 2024	Jul 11, 2024	SEC EDGAR
Current report	8-K	Jun 21, 2024	Jun 24, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Akebia Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AKBA.

Compare: AKBA vs AGIO · AKBA vs ARDX · AKBA vs AUPH · AKBA vs TVTX · AKBA vs AMRN

Revenue growth-12.4% · median 21.0%

Gross margin78.9% · median 93.8%

Operating margin-15.7% · median -18.2%

Net margin-22.6% · median -12.4%

Company	Revenue	Growth
TVTX	$651.04M	+49.4%
ARDX	$450.89M	+16.8%
AUPH	$321.74M	+21.0%
AKBA	$197.20M	-12.4%
AMRN	$176.11M	-22.3%
AGIO	$140.84M	+214.4%

Company

Next earnings (est.): Feb 25, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 194
Held by institutions: 39.7%
Auditor: Ernst & Young LLP
SEC CIK: 1517022

Advertisement
300 × 250

See a number that looks wrong?